Development of Crohn’s Disease during the Course of HLA B27+ Juvenile Idiopathic Arthritis
Authors:
M. Huml; J. Sýkora; V. Lád; K. Siala; R. Pomahačová; R. Vondráková 1
Authors place of work:
Dětská klinika UK LF a FN, Plzeň
přednosta doc. MUDr. J. Kobr, PhD.
; Radiodiagnostická klinika FN, Plzeň
přednosta doc. MUDr. B. Kreuzberg, CSc.
1
Published in the journal:
Čes-slov Pediat 2009; 64 (1): 22-27.
Category:
Case Report
Summary
Authors regard an extraordinary case of a 15-year-old boy with longstanding juvenile idiopathic arthritis (JIA), who developed fistulizing Crohn’s disease (CD).
This patient had been treated for rheumatic factor negative JIA for 4 years. Despite intensive therapy (low-dose methotrexate, corticosteroids), with each successive joint involvement his diagnosis was reclassified to enthesitis-related arthritis (ERA). ERA is considered to be a subgroup of JIA and formerly known as juvenile ankylosing spondylitis (JAS). Our patient had been operated on a perianal abscess, at that standpoint joint manifestations had deteriorated. Five months later, he was referred to our unit for draining perianal fistula since surgery. This child was diagnosed for perianal CD according to standard clinico-pathophysiological criteria. Fecal calprotectin as a non-invasive marker of gastrointestinal inflammation was elevated regarding age (>150 µg/g). Pancreatic organ specific antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA) were positive. Heterozygous 4G/5G genotype for the type 1 plasminogen activator inhibitor (PAI-1) was discovered. He was then given infliximab and immunosuppressive therapy with prompt reverse of fistula drainage and joint manifestation also rapidly resolved.
Authors discuss the published case and summarize the links between JIA a CD in the clinical and basic science literature. The pathophysiology of these two diseases is not fully understood and may relate to immune-mediated mechanisms. Out data may contribute to a better understanding of the pathophysiology underlying CD. Based on our findings, to our best knowledge, this is the first case demonstrating CD onset in JIA in childhood.
Key words:
Crohn’s disease, juvenile idiopathic arthritis, HLA B27
Zdroje
1. Veys EM, Mielant H. Enteropathic arthropathies. In Klippel JH, Dieppe PA, et al. Rheumatology. 2nd ed. London: Mosby,1999;6: 1–7.
2. Fink CW, and the ILAR Task Force for Classifica tion Criteria. A proposal for the development of classification criteria for the idiopathic arthritides of childhood. J. Rheumatol. 1995;22: 1566–1569.
3. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J. Rheumatol. 1998;25: 1991–1994.
4. Dougados M, van der Linden S, Juhlin R, et. al. The European Spondyloarthropathy Study. Group premilitary criteria for the classification of spondyloarthropathies. Arthritis Rheum.1991;34: 1218–1230.
5. Jacques P, Mielants H. The intimate relationship between gut and joint in spondyloarthropathies. Curr. Opin. Rheumatol. 2007;19: 353–357.
6. Peeters H, Cruyssen BV, Mielants H. Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J. Gastroenterol. Hepatol. 2008;23: 132–137.
7. Štolfa J. Spondylartritidy. In Hrba J, Štolfa J, Pavelka K. Artritidy a artróza v ordinaci praktického lékaře. Praha: Apotex, 1999: 19–43.
8. Mielants H, Veys EM, Cuvelier C, et al. Ileocolonoscopic findings in seronegative spondylarthropathies. Br. J. Rheumatol.1988;27: 95–105.
9. Jaskowski T, Litwin C, Hill H. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin. Vaccine Immunol. 2006;13: 655–660.
10. Sý́kora J, Varvařovská J, Stožický F, et al. Organ-specific antibodies in children with idiopathic inflammatory bowel disease and their use in clinical practice (Orgánově specifické́ protilá́tky u dětí s idiopatický́mi střevními záněty a jejich užití v klinické praxi). Čas. Lék. čes. 2000;139: 735–737.
11. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Inflammatory Bowel Disease in Children and Adolescents: Recommendations for Diagnosis – The Porto Criteria. J. Pediatr. Gastroenterol. Nutr. 2005;41: 1–7.
12. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123: 714–718.
13. Ho P, Bruce IN, Silman A, et al. Evidence for common genetic control in pathways of inflammation for Crohn’s disease and psoriatic arthritis. Arthritis Rheum. 2005;52: 3596–3602.
14. Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN Study). J. Rheumatol. 2002;29: 511–515.
15. Quartier P, Prieur AM. Juvenile idiopathic arthritis. Rev. Prat. 2007;57: 1171–1178.
16. Zhang H, Phang D, Laxer RM, et al. Evolution of the T cell receptor beta repertoire from synovial fluid T cells of patients with juvenile onset rheumatoid arthritis. J. Rheumatol. 1997;24: 1396–1402.
17. Stastny P, Fernandez-Viňa M, Cerna M, et al. Sequences of HLA alleles associated with arthritis in adults and children. J. Rheumatol. 1993;37(Suppl): 5–8.
18. Cerna M, Vavrincova P, Havelka S, et al. Class II alleles in juvenile arthritis in Czech children. J. Rheumatol. 1994;21: 159–164.
19. Forcione DG, Sands B, Isselbacher KJ, et al. An increased risk of Crohn’s disease in individuals who inherit the HLA class II DRB3*0301 allele. Natl. Acad. Sci.. 1996;93: 5094–5098.
20. Purrmann J, Zeidler H, Bertrams J, et al. HLA antigens in ankylosing spondylitis associated with Crohn’s disease. Increased frequency of the HLA phenotype B27, B44. J. Rheumatol. 1988;15: 1658-1666.
21. Kroeger KM, Carville KS, Abraham L. The 308 tumor necrosis factor-alpha promoter polymorphisms effects transcription. Mol. Immunol. 1997;34: 391Y9.
22. Sýkora J, Šubrt I, Dědek P, et al. Cytokine tumor necrosis factor alpha A promoter gene polymorphism at position 308 G/A and pediatric inflammatory bowel disease: implications inulcerative colitis and Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. 2006;42:479–487.
23. Sans M, Tassies D, Pelliese M, et al. The 4G/4G genotype of the 4G/5G polymorfism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in the patients with Crohn’s disease. Aliment. Pharmacol. Ther. 2003;17: 1039–1047.
24. De Keyser F, Mielants H. The gut in ankylosing spondylitis and other spondyloarthropathies: inflammation beneath the surfaře. J. Rheumatol. 2003;30: 11.
25. Mielants H, Veys EM, Curvelier C, et al. Ilecolonoscopic finding seronegative spondyloarthropathies. Br. J. Rheumatol. 1988;27: 95–105.
26. De Keyser F, Baeten D, Van den Bosch F, et al. Gut inflammation and spondyloarthropathies. Curr. Rheumatol. Rep. 2002;4: 525–532.
27. De Vos M, Mielants H, Cuvelier C, et al. Long term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110: 1696–1703.
28. Baeten D, Demetter P, Cuvelier C, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J. Pathol. 2002;196: 343–350.
29. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J. Pediatr. 1999;134: 447–452.
30. Hoffman EA, Demetter P, Peeters M, et al. Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann. Rheum. Dis. 2003;62:455–459.
31. Cryer B. NSAID gastrointestinal toxicity. Curr. Opin. Gastroenterol. 2000;16: 495–502.
32. Lukáš M. Gastropatie a entetopatie z nesteroidních antirevmatik. Med. pro Praxi 2006;11: 489–492.
33. Graves M, Pochápán M. Asymptomatic ileitis: past, prezent, and future. J. Clin. Gastroenterology 2006;40: 281–284.
34. Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002;46: 755–765.
35. Katsuaki K, Kazuhiko I, Yasuo I, et al. Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis. Clin. Rheumatol. 2008;27: 347–353
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2009 Číslo 1
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Prevention of CAN Syndrome in the Child
- Anatomical, Embryological and Ethical Aspect of Conjoined (Siamese) Twins
- Recommendation for Diagnostics and Therapy of Hypertension in Children and Adolescents Elaborated by the Working Group of Pediatric Cardiology
- Development of Crohn’s Disease during the Course of HLA B27+ Juvenile Idiopathic Arthritis